Drug
Acam2000
Acam2000: highest development phase Phase 3, developed by Emergent BioSolutions. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Emergent BioSolutions
Trials
| Drug | Phase | Indication |
|---|---|---|
| ACAM2000 NCT01158157 | Phase 3 | Smallpox Vaccine Adverse Reaction |
Latest
No recent events.
Follow Acam2000 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.